Velusetrag: Phase II started

Theravance and Alfa Wassermann began the double-blind, placebo-controlled, 3-way crossover Phase II Study 0093 trial in about 32 patients to evaluate 5, 15 and 30 mg oral velusetrag once daily for 1 w...